Search

Your search keyword '"Signoriello E."' showing total 208 results

Search Constraints

Start Over You searched for: Author "Signoriello E." Remove constraint Author: "Signoriello E."
208 results on '"Signoriello E."'

Search Results

5. Signs and symptoms of COVID-19 in patients with multiple sclerosis

7. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis

8. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis

9. Signs and symptoms of COVID-19 in patients with multiple sclerosis

10. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

11. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

12. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

14. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

15. Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis

17. On the topochronic map of the human brain dynamics

18. Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

19. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

20. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

21. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

22. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

23. Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis

29. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study

30. Disability assessment in the Google Maps era: a pilot study

31. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

32. Extended interval dosing of natalizumab: is efficacy preserved?

34. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

35. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

36. Comparative effectiveness of dimethyl fumarate, teriflunomide, interferon-beta and glatiramer acetate on newly diagnosed patients: a propensity score-matched analysis from a multicenter Italian group

40. Comorbidities affect treatment choice and persistence in RRMS: a real-life multicenter study

41. To switch therapies in RRMS: why and when? A real-life multicentre study

42. THC:CBD discontinuation in a large population of Italian multiple sclerosis patients (SA.FE. study)

43. THC:CBD oromucosal spray as an add-on therapy in a large population of Italian multiple sclerosis patients (SA.FE. study)

44. Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis.

45. Clinical activity after fingolimod cessation: disease reactivation or rebound?

48. Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.

49. Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment

50. Mri activity and extended interval of natalizumab dosing: a multicenter italian study

Catalog

Books, media, physical & digital resources